MARKET

MCRB

MCRB

Seres
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.510
-0.990
-18.00%
After Hours: 4.360 -0.15 -3.33% 19:59 07/10 EDT
OPEN
5.50
PREV CLOSE
5.50
HIGH
5.54
LOW
4.480
VOLUME
1.31M
TURNOVER
--
52 WEEK HIGH
6.75
52 WEEK LOW
2.150
MARKET CAP
327.42M
P/E (TTM)
-4.4159
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MCRB stock price target is 8.04 with a high estimate of 12.50 and a low estimate of 3.750.

EPS

MCRB News

More
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)
Benzinga · 3d ago
Seres Therapeutics (MCRB) in Focus: Stock Moves 10.8% Higher
Zacks · 4d ago
Seres Therapeutics Halted On Volatility
Benzinga · 4d ago
Implied Volatility Surging for Seres Therapeutics (MCRB) Stock Options
Zacks · 5d ago
Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing
PR Newswire · 5d ago
3 Under-the-Radar Penny Stocks Gearing up for Gains
TipRanks · 06/25 16:23
Seres names Sage's executive as commercial leader
Seeking Alpha - Article · 06/22 13:31
Seres Therapeutics Appoints Terri Young, Ph.D., R.Ph., Experienced Commercial Leader, as Executive Vice President, Chief Commercial and Strategy Officer
Seres Therapeutics announces the appointment of Terri Young, Ph.D., R.Ph., as Executive Vice President, Chief Commercial and Strategy Officer.
Business Wire · 06/22 11:00

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About MCRB

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.
More

Webull offers kinds of Seres Therapeutics Inc stock information, including NASDAQ:MCRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MCRB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MCRB stock methods without spending real money on the virtual paper trading platform.